online shoes store xkshoes,here check the latest yeezy shoes click here.

know more about 2020 nike and adidas soccer cleats news,check shopcleat and wpsoccer.

IEBT - Drug-Free Workplace Programs Administrator and Nationwide Mobile Drug Testing Network

 
 
 

Regulation Alert

 

Link to IEBT Home Page
About IEBT
Services Offered by IEBT
Types of Drug Testing and Services Offered
Types of Alcohol Testing and Services Offered
Drug and Alcohol Free Workplace Administration
Why a Drug-Free Workplace?
Training Services Offered
CLICK HERE to Logon to Your Scheduled IEBT Training Class
BWC Drug Free Workplace Program Discounts
Grant Information Page
Drug and Alcohol Testing Regulations
IEBT Client Page Link Button
Link Tree of All of Pages on This Website
How to Contact IEBT - Address, Phone Numbers, etc.

 
 
 
 
 
 


 

DOT Changes for 2018

 
Effective January 1st, the Department of Transportation is amending its drug testing program regulation to add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine (MDEA) as a confirmatory test analyte.

New DOT drug test panel is still a 5-Panel Test.

The four semi-synthetic opioids (hydrocodone, hydromorphone, oxymorphone, and oxycodone) being added to the DOT panel are all a part of the Opiate drug family. Some common names for these semi-synthetic opioids include OxyContin�, Percodan�, Percocet�, Vicodin�, Lortab�, Norco�, Dilaudid�, Exalgo�. The Opiate drug, including codeine, morphine and heroin, has been a part of the five drugs on the DOT testing panel since inception. DOT is simply expanding the testing for 4 more types or iterations of the Opiate drug.

Similarly, the removal of MDEA and addition of MDA are a part of the Amphetamine family of drugs. Thus, the new DOT panel is still considered to be a 5-panel drug screen.

Employers must inform employees of these changes.

All affected employees need to be aware of these changes to your DOT and (if applicable) Non-DOT testing program. It is advised that each employer provide a written notice of these changes to your employee and to document the notification.

New DOT plan expected in early 2018.

NCMS is currently working on making the applicable revisions to the NCMS DOT/PHMSA model plan. This new plan will be available to contractors, monitored by NCMS, in the first quarter of 2018. Notifications will be sent out at that time.

DOT Drug Changes for Jan 1st, 2018

 

 

Initial test analyte

 

Initial test cutoff 1

 

Confirmatory test analyte

Confirmatory test cutoff con- centration

Marijuana metabolites (THCA) 2 ..............

50 ng/mL3 ...............................................

THCA .....................................................

15 ng/mL.

Cocaine metabolite (Benzoylecgonine) ...

150 ng/mL 3 ............................................

Benzoylecgonine ....................................

100 ng/mL.

Codeine/ ..................................................

2000 ng/mL ............................................

Codeine ..................................................

2000 ng/mL.

Morphine

 

Morphine ................................................

2000 ng/mL.

Hydrocodone/ ..........................................

300 ng/mL ..............................................

Hydrocodone ..........................................

100 ng/mL.

Hydromorphone

 

Hydromorphone .....................................

100 ng/mL.

Oxycodone/ .............................................

100 ng/mL ..............................................

Oxycodone .............................................

100 ng/mL.

Oxymorphone

 

Oxymorphone .........................................

100 ng/mL.

6-Acetylmorphine .....................................

10 ng/mL ................................................

6-Acetylmorphine ...................................

10 ng/mL.

Phencyclidine ..........................................

25 ng/mL ................................................

Phencyclidine .........................................

25 ng/mL.

Amphetamine/ .........................................

500 ng/mL ..............................................

Amphetamine .........................................

250 ng/mL.

Methamphetamine

 

Methamphetamine .................................

250 ng/mL.

MDMA 4/MDA 5 ........................................

500 ng/mL ..............................................

MDMA ....................................................

250 ng/mL.

 

 

MDA .......................................................

250 ng/mL.

1 For grouped analytes (i.e., two or more analytes that are in the same drug class and have the same initial test cutoff):

Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross-reactivity of the immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be used for the analytes within the group.

Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. At least one analyte within the group must have a concentration equal to or greater than the initial test cutoff or, alternatively, the sum of the analytes present (i.e., equal to or greater than the laboratory�s validated limit of quantification) must be equal to or greater than the initial test cutoff.

2 An immunoassay must be calibrated with the target analyte, D-9-tetrahydrocannabinol-9-carboxylic acid (THCA).

3 Alternate technology (THCA and Benzoylecgonine): When using an alternate technology initial test for the specific target analytes of THCA and Benzoylecgonine, the laboratory must use the same cutoff for the initial and confirmatory tests (i.e., 15 ng/mL for THCA and 100ng/mL for Benzoylecgonine).

4 Methylenedioxymethamphetamine (MDMA).

5 Methylenedioxyamphetamine (MDA).

 



 


 

Today businesses, no matter how small or large, can partner with IEBT to insure the benefits that a Drug and Alcohol Free Workplace has to offer.  Whether you have an existing program, or are looking to implement one, rest assured that a company with nearly 20 years of experience in this industry can serve your needs no matter what they may be.

Contact us Today for a Free Consultation!

IEBT - Free Consultation and Evaluation

IEBT SERVICES AND PRODUCTS
Applicable Services Available On-Site at Your Company's Location


Workplace Services

Urine Drug Testing 
Hair Drug Testing 
Legal Hair Drug Testing 
Level of Detection Hair Testing 
Breath Alcohol Testing 
Saliva Alcohol testing 
Urine Alcohol Testing 
Instant Urine Drug Testing 
Expert Witness 
Medical Review Officer (MRO) 
Full Third Party Administration 
Random Selections 
DFWP Policy Development

Bureau of Workers' Comp. (BWC) 
Premium Discount Programs 
BWC-DFWP Policy Development 
Employee Training 
Supervisor Training 
Breath Alcohol Testing 
Saliva Alcohol testing
Urine Drug Testing 
Expert Witness 
Medical Review Officer (MRO) 
Full Third Party Administration 
Random Selections 


DOT Services

Urine Drug Testing
Breath Alcohol Testing (BAT)
Saliva Alcohol Testing (STT)
Physical Examinations
Supervisor Training
Expert Witness
Medical Review Officer (MRO)
Full Third Party Administration
Random Selections

DOT Policy Development
FMCSA (CDL Drivers)
USCG (Coast Guard)
RSPA (Pipeline)

Industry Training
BAT Training
STT Training
Collector Training
Instructor Training

Products
Instant Drug Test Kits
Breath Alcohol Equipment
Drug & Alcohol Supplies
Training Supplies

 

Why a Drug Free Workplace Program? | Drug and Alcohol Testing Administration | Worker's Compensation Discount Program | Alcohol Testing Services | Drug Testing Services | Training and Education Services | Home Page | About Us | Services | Client List | Online Training Login | Regulations | Grants | Sitemap | Contact Us

 

1685 Southeast Avenue - Tallmadge, OH, 44278 - 800-628-5106

?Copyright 2006, IEBT corporation